NORTHWEST BIOTHERAPEUTICS INC
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $1.4M | $1.9M | $1.7M | $1.0M | $1.3M | $2.4M | $412.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $28.8M | $34.9M | $27.7M | $35.5M | $20.3M | $33.6M | $14.1M | $18.2M |
| SG&A Expense | $32.5M | $33.0M | $29.7M | $33.4M | $33.4M | $54.3M | $16.3M | $22.5M |
| Operating Income | $-59.9M | $-66.5M | $-55.5M | $-67.2M | $-52.7M | $-86.6M | $-28.0M | $-41.5M |
| Operating Margin | -4,347.9% | -4,812.4% | -2,873.1% | -3,991.7% | -5,244.0% | -6,708.4% | -1,161.0% | -10,068.2% |
| Interest Expense | — | — | $5.2M | $6.1M | $5.0M | $8.5M | $3.0M | $9.9M |
| Pretax Income | $-60.7M | $-83.8M | — | — | — | — | — | — |
| Income Tax Expense | $-537.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-60.2M | $-83.8M | $-62.6M | $-105.0M | $179.1M | $-529.8M | $-20.8M | $-35.8M |
| Net Margin | -4,365.9% | -6,062.1% | -3,240.1% | -6,240.8% | 17,823.5% | -41,039.6% | -863.6% | -8,687.9% |
| EPS (Basic) | $-0.04 | $-0.07 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $-0.04 | $-0.07 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 1.46B | 1.24B | 1.24B | 1.13B | 969.6M | 804.9M | 626.2M | 580.75B |
| Shares Outstanding (Diluted) | 1.46B | 1.24B | 1.24B | 1.13B | 1.12B | 804.9M | 626.2M | 580.75B |
| Dividends Per Share | — | — | — | — | — | — | — | — |